[Cannabidiol (CBD): Analytical and toxicological aspects]. 2023

Jean-Claude Alvarez, and Anne-Laure Pelissier, and Patrick Mura, and Jean-Pierre Goullé
Laboratoire de pharmacologie/toxicologie, CHU Garches, université Paris-Saclay (Versailles-St Quentin-en-Yvelines), plateforme de spectrométrie de masse MasSpecLab, UFR médecine Simone Veil, Inserm U-1018, CESP, Équipe MOODS, 92380 Garches, France. Electronic address: jean-claude.alvarez@aphp.fr.

Cannabidiol (CBD) is a phytocannabinoid present in cannabis, obtained either by extraction from the plant or by synthesis. The latter has the advantage of being pure and contains few impurities, unlike CBD of plant origin. It is used by inhalation, ingestion or skin application. In France, the law stipulates that specialties containing CBD may contain up to 0.3% of tetrahydrocannabinol (THC), the psychoactive principle of cannabis. From an analytical point of view, it is therefore important to be able to quantify the two compounds as well as their metabolites in the various matrices that can be used clinically or forensically, in particular saliva and blood. The transformation of CBD into THC, which has long been suggested, appears to be an analytical artifact under certain conditions. CBD is not without toxicity, whether acute or chronic, as seems to attest to the serious adverse effects recorded by pharmacovigilance during the experiment currently being conducted in France by the Agence Nationale de Sécurité du Médicament et des Produits de Santé. Although CBD does not seem to modify driving abilities, driving a vehicle after consuming CBD containing up to 0.3% THC, and sometimes much more in products bought on the internet, can lead to a positive result in screening and confirmation tests by law enforcement agencies, whether salivary or blood tests, and therefore lead to a legal sanction.

UI MeSH Term Description Entries
D002185 Cannabidiol Compound isolated from Cannabis sativa extract. 1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-,Epidiolex
D005602 France A country in western Europe bordered by the Atlantic Ocean, the English Channel, the Mediterranean Sea, and the countries of Belgium, Germany, Italy, Spain, Switzerland, the principalities of Andorra and Monaco, and by the duchy of Luxembourg. Its capital is Paris. Corsica,Saint Pierre and Miquelon,Miquelon and Saint Pierre,Miquelon and St. Pierre,St. Pierre and Miquelon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013759 Dronabinol A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound. THC,Tetrahydrocannabinol,delta(9)-THC,9-ene-Tetrahydrocannabinol,Marinol,Tetrahydrocannabinol, (6a-trans)-Isomer,Tetrahydrocannabinol, (6aR-cis)-Isomer,Tetrahydrocannabinol, (6aS-cis)-Isomer,Tetrahydrocannabinol, Trans-(+-)-Isomer,Tetrahydrocannabinol, Trans-Isomer,delta(1)-THC,delta(1)-Tetrahydrocannabinol,delta(9)-Tetrahydrocannabinol,9 ene Tetrahydrocannabinol,Tetrahydrocannabinol, Trans Isomer
D064420 Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals. Drug-Related Side Effects and Adverse Reaction,Adverse Drug Event,Adverse Drug Reaction,Drug Side Effects,Drug Toxicity,Side Effects of Drugs,Toxicity, Drug,Adverse Drug Events,Adverse Drug Reactions,Drug Event, Adverse,Drug Events, Adverse,Drug Reaction, Adverse,Drug Reactions, Adverse,Drug Related Side Effects and Adverse Reaction,Drug Related Side Effects and Adverse Reactions,Drug Side Effect,Drug Toxicities,Effects, Drug Side,Reactions, Adverse Drug,Side Effect, Drug,Side Effects, Drug,Toxicities, Drug

Related Publications

Jean-Claude Alvarez, and Anne-Laure Pelissier, and Patrick Mura, and Jean-Pierre Goullé
January 2021, Journal of addiction medicine,
Jean-Claude Alvarez, and Anne-Laure Pelissier, and Patrick Mura, and Jean-Pierre Goullé
July 2018, Medicine, science, and the law,
Jean-Claude Alvarez, and Anne-Laure Pelissier, and Patrick Mura, and Jean-Pierre Goullé
September 2021, Epilepsy & behavior : E&B,
Jean-Claude Alvarez, and Anne-Laure Pelissier, and Patrick Mura, and Jean-Pierre Goullé
April 2002, Therapeutic drug monitoring,
Jean-Claude Alvarez, and Anne-Laure Pelissier, and Patrick Mura, and Jean-Pierre Goullé
January 2020, Substance use & misuse,
Jean-Claude Alvarez, and Anne-Laure Pelissier, and Patrick Mura, and Jean-Pierre Goullé
February 2022, Cancers,
Jean-Claude Alvarez, and Anne-Laure Pelissier, and Patrick Mura, and Jean-Pierre Goullé
August 2020, Pharmaceuticals (Basel, Switzerland),
Jean-Claude Alvarez, and Anne-Laure Pelissier, and Patrick Mura, and Jean-Pierre Goullé
January 2024, International archives of otorhinolaryngology,
Jean-Claude Alvarez, and Anne-Laure Pelissier, and Patrick Mura, and Jean-Pierre Goullé
February 2023, Chemical research in toxicology,
Jean-Claude Alvarez, and Anne-Laure Pelissier, and Patrick Mura, and Jean-Pierre Goullé
April 1989, Journal of chromatography,
Copied contents to your clipboard!